• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    The Bull Case For Tarsus Pharmaceuticals (TARS) Could Change Following Sharp EPS Estimate Cuts Amid Rising Sales

    Simply Wall St·08/01/2026 18:14:30
    语音播报
    • Tarsus Pharmaceuticals recently faced significantly lowered consensus earnings-per-share estimates and a low analyst ranking ahead of its June 2026 quarterly results, even as revenue was projected to increase year over year.
    • This combination of weaker profit expectations and growing sales highlights a tension between top-line momentum and concerns about the company’s near-term earnings profile.
    • Now we’ll examine how this sharp downward revision in earnings expectations may affect Tarsus Pharmaceuticals’ previously optimistic long-term investment narrative.

    Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

    Tarsus Pharmaceuticals Investment Narrative Recap

    To own Tarsus Pharmaceuticals, you need to believe XDEMVY can keep building a durable, high-margin franchise while the pipeline slowly broadens the story beyond a single product. The recent sharp cut to consensus EPS ahead of the June 2026 report raises questions about how quickly that growth can translate into cleaner earnings, but it does not fundamentally alter the near term catalyst of XDEMVY uptake or the key risk around managing high commercial spending against still negative profitability.

    The recent US$15,000,000 milestone payment tied to XDEMVY’s approval in China is especially relevant here, because it underscores how revenue can grow even as earnings expectations soften. That international contribution, together with rising XDEMVY sales, may help support the top line while management works through higher SG&A and an interim commercial leadership transition, both of which sit at the heart of the current earnings uncertainty.

    But against that backdrop, you should be aware that if prescription growth ever slows materially...

    Read the full narrative on Tarsus Pharmaceuticals (it's free!)

    Tarsus Pharmaceuticals' narrative projects $1.1 billion revenue and $632.5 million earnings by 2029. This requires 28.3% yearly revenue growth and about a $681 million earnings increase from -$48.3 million today.

    Uncover how Tarsus Pharmaceuticals' forecasts yield a $94.11 fair value, a 59% upside to its current price.

    Exploring Other Perspectives

    TARS 1-Year Stock Price Chart
    TARS 1-Year Stock Price Chart

    While consensus once saw Tarsus reaching about US$988,000,000 in revenue and US$188,000,000 in earnings by 2029, the lowest analysts already stressed how payer pressure and heavier spending could quickly reshape those forecasts, reminding you that even before this earnings revision, opinion on Tarsus’s risk reward profile was far from settled.

    Explore 4 other fair value estimates on Tarsus Pharmaceuticals - why the stock might be worth just $88.00!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Ready For A Different Approach?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.